Transcription control by the ENL YEATS domain in acute leukemia
暂无分享,去创建一个
S. Orkin | Dennis L. Buckley | J. Bradner | Feng Zhang | N. Sanjana | H. Seo | O. Shalem | G. Winter | Huafeng Xie | B. Nabet | Rhamy Zeid | S. Dhe-Paganon | Joshiawa Paulk | Justin M. Roberts | Amanda L. Souza | S. Dastjerdi | Michael A. Erb | Thomas G. Scott | Bin E. Li | N. K. Offei-Addo
[1] Haipeng Guan,et al. Molecular Coupling of Histone Crotonylation and Active Transcription by AF9 YEATS Domain. , 2016, Molecular cell.
[2] B. Strahl,et al. The Taf14 YEATS domain is a reader of histone crotonylation , 2016, Nature chemical biology.
[3] S. Armstrong,et al. Drugging Chromatin in Cancer: Recent Advances and Novel Approaches. , 2015, Molecular cell.
[4] E. Lander,et al. Identification and characterization of essential genes in the human genome , 2015, Science.
[5] Łukasz M. Boryń,et al. Transcriptional plasticity promotes primary and acquired resistance to BET inhibition , 2015, Nature.
[6] B. Strahl,et al. Association of Taf14 with acetylated histone H3 directs gene transcription and the DNA damage response , 2015, Genes & development.
[7] James E. Bradner,et al. Phthalimide conjugation as a strategy for in vivo target protein degradation , 2015, Science.
[8] J. Kinney,et al. Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains , 2015, Nature Biotechnology.
[9] Wei Li,et al. AF9 YEATS Domain Links Histone Acetylation to DOT1L-Mediated H3K79 Methylation , 2014, Cell.
[10] Neville E. Sanjana,et al. Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells , 2014, Science.
[11] Robert A Copeland,et al. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. , 2013, Blood.
[12] Thomas A. Milne,et al. RUNX1 Is a Key Target in t(4;11) Leukemias that Contributes to Gene Activation through an AF4-MLL Complex Interaction , 2013, Cell reports.
[13] Christopher J. Ott,et al. BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. , 2012, Blood.
[14] S. Lowe,et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia , 2011, Nature.
[15] R. Young,et al. BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc , 2011, Cell.
[16] Caleb K. Chan,et al. Human Polymerase-Associated Factor complex (PAFc) connects the Super Elongation Complex (SEC) to RNA polymerase II on chromatin , 2011, Proceedings of the National Academy of Sciences.
[17] Lars Bullinger,et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. , 2011, Cancer cell.
[18] Yonghong Xiao,et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. , 2011, Cancer cell.
[19] M. Cleary,et al. A higher-order complex containing AF4 and ENL family proteins with P-TEFb facilitates oncogenic and physiologic MLL-dependent transcription. , 2010, Cancer cell.
[20] N. Hacohen,et al. Highly parallel identification of essential genes in cancer cells , 2008, Proceedings of the National Academy of Sciences.
[21] Richard A Young,et al. Aberrant chromatin at genes encoding stem cell regulators in human mixed-lineage leukemia. , 2008, Genes & development.
[22] Xiaobo Xia,et al. H3K79 methylation profiles define murine and human MLL-AF4 leukemias. , 2008, Cancer cell.
[23] A. Chinnaiyan,et al. A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification. , 2007, Blood.
[24] Scott A. Armstrong,et al. MLL translocations, histone modifications and leukaemia stem-cell development , 2007, Nature Reviews Cancer.
[25] B. Peterlin,et al. Controlling the elongation phase of transcription with P-TEFb. , 2006, Molecular cell.
[26] J. Hess,et al. The eleven-nineteen-leukemia protein ENL connects nuclear MLL fusion partners with chromatin , 2005, Oncogene.
[27] Yi Zhang,et al. hDOT1L Links Histone Methylation to Leukemogenesis , 2005, Cell.
[28] R. Slany,et al. When epigenetics kills: MLL fusion proteins in leukemia , 2005, Hematological oncology.
[29] B. Smith,et al. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. , 2002, Blood.
[30] Shannon R. Magari,et al. Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[31] M. Cleary,et al. ENL, the gene fused with HRX in t(11;19) leukemias, encodes a nuclear protein with transcriptional activation potential in lymphoid and myeloid cells. , 1994, Blood.